Navigation Links
Antidepressents may Lower Bone Density in Older People

The class of antidepressant medications known as selective serotonin reuptake inhibitors may be associated with an increased rate of bone loss in older men and women. Selective serotonin reuptake inhibitors (SSRIs) treat depression by inhibiting the protein that transports serotonin, a neurotransmitter involved in sleep and depression.

This protein has recently been discovered in bone as well, raising the possibility that SSRIs may affect bone density and the risk of fracture. SSRIs account for about 62 percent of antidepressant prescriptions in the United States, and are often prescribed to the elderly.

Susan J. Diem, M.D., M.P.H., University of Minnesota, Minneapolis, and colleagues studied 2,722 older women (average age 78.5 years) beginning in 1997 through 1999. At that time and again an average of 4.9 years later, researchers measured womens total hip bone density and also that of two subregions.

At each visit, the participants were asked to bring in all the medications they had used within the past two weeks, including SSRIs and tricyclic antidepressants, which work through a different mechanism.

A total of 198 (7.3 percent) of the women were SSRI users, 118 (4.3 percent) took tricyclic antidepressants and 2,406 (88.4 percent) took neither (those who took both were not included in the analysis).

After the researchers adjusted for other factors affecting bone density and antidepressant use, including depression severity and calcium supplement use, bone mineral density at the hip decreased 0.82 percent in SSRI users. This compared with a decrease of 0.47 percent among those who used tricyclic antidepressants and also in those who did not take any antidepressants. Higher rates of bone loss were also observed at the two hip subregions among SSRI users.

One potential explanation for our findings is that SSRI use may have a direct deleterious effect on bone, the authors write. This the ory is supported by findings of in vitro and in vivo laboratory investigations. Some data suggest that SSRIs may interfere with the function of osteoclasts and osteoblasts, cells responsible for the regular breaking down and rebuilding of bone in the body.

Our findings suggest that, in this cohort, use of SSRIs is associated with increased rates of hip bone loss, the authors conclude. Although some of this association may have occurred because women who were prescribed SSRIs were different from those who were not prescribed SSRIs, further investigation of SSRI use and rates of change in bone mineral density in other populations with longer follow-up is warranted given the recent description of serotonin transporters in bone.

In a related paper, Elizabeth M. Haney, M.D., of Oregon Health & Sciences University, Portland, and colleagues conducted a similar study with 5,995 men age 65 and older (average age 73.7). The mens bone density at the hip, including subregions, and at the base of the spine were measured between 2000 and 2002. Participants were asked to bring all medications to their clinic visit, where they were also given a physical examination and asked about other health and lifestyle factors.

A total of 160 (2.7 percent) men reported using SSRIs, 99 (1.7 percent) reported using tricyclic antidepressants and 52 (0.9 percent) reported using trazodone, a third type of antidepressant. Total hip bone mineral density was 3.9 percent lower among SSRI users than among men who didnt use any antidepressants.

Similarly, spine bone mineral density was 5.9 percent lower among SSRI users than among non-users. There was no significant difference in either hip or spine density between men who took tricyclic antidepressants or trazodone and those who did not take antidepressants.

These associations are biologically plausible and clinically important, the authors conclude. Because SSRI use is prevalent in t he general population, our findings have a potentially important public health impact. If confirmed, people using SSRIs might be targeted for osteoporosis screening and preventive intervention.


'"/>




Related medicine news :

1. Simvastatin Plus Niacin May Lower Heart Risks
2. Ritalin May Lower Cocaine Abuse
3. Eating More Often May Help Lower Cholesterol
4. Lower surgical volume linked to higher death rate
5. Lowering blood pressure beneficial for PAD patients
6. Lower chance of bone fracture with Vitamin D supplementation
7. Tea Pill Lowers Cholesterol
8. Aspirin Lowers Leukemia Risk
9. Almonds Help Lower Cholesterol
10. Lowering Risk of Breast Cancer Recurrence
11. Drug to Lower Cholesterol Underused
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
(Date:12/7/2016)... VA (PRWEB) , ... December 07, 2016 , ... ... are celebrating the passage of the most comprehensive mental health systems reform legislation ... the support of the President, and the commitment of our elected officials to ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... SINGAPORE , BEIJING , and ... a leading commercial provider of genomic services and solutions with ... a Singapore biotechnology company; and the ... today that NovogeneAIT Genomics Singapore (NovogeneAIT) – a new joint ... whole genome sequencing (WGS) centre at Biopolis, Singapore ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology: